ClinicalTrials.govrestricted
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
ClinicalTrials.gov study NCT01124526. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4